Current Liabilities

Derivative Liabilities - Fair Value

Biogen Derivative Liabilities - Fair Value decreased by 32.6% to $38.20M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ4 2018
Last reportedQ1 2026

How to read this metric

An increase indicates higher potential cash outflows or increased market exposure to counterparties.

Detailed definition

This represents the total fair value of derivative financial instruments that are in a net liability position at the rep...

Peer comparison

Standard disclosure for all banks with significant trading or derivative portfolios.

Metric ID: derivative_liabilities_fair_value

Historical Data

2 periods
 Q4 '25Q1 '26
Value$56.70M$38.20M
QoQ Change—-32.6%
Range$38.20M – $56.70M

Derivative Liabilities - Fair Value at Other Companies

Merck & Co. logo
Merck & Co.MRKView metric
Gilead Sciences logo
Gilead SciencesGILDView metric

Frequently Asked Questions

What is Biogen's derivative liabilities - fair value?
Biogen (BIIB) reported derivative liabilities - fair value of $38.20M in Q1 2026.
What does derivative liabilities - fair value mean?
The current market value of all derivative contracts where the bank is in a net owing position.